VNRX logo

VNRX
VolitionRX Ltd

1,694
Mkt Cap
$26.28M
Volume
3.77M
52W High
$0.94
52W Low
$0.1502
PE Ratio
-0.76
VNRX Fundamentals
Price
$0.1658
Prev Close
$0.1724
Open
$0.1738
50D MA
$0.2094
Beta
0.41
Avg. Volume
26.47M
EPS (Annual)
-$0.2186
P/B
-0.61
Rev/Employee
$23,031.79
$36.31
Loading...
Loading...
News
all
press releases
VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update
VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update PR Newswire...
PR Newswire·12d ago
News Placeholder
More News
News Placeholder
VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium
VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in...
PR Newswire·12d ago
News Placeholder
Volition Announces Mayo Clinic Study Demonstrates Nu.Q Concentrations are Elevated in Trauma Patients
Volition Announces Mayo Clinic Study Demonstrates Nu.Q Concentrations are Elevated in Trauma Patients Volition Announces Mayo Clinic Study Demonstrates Nu.Q Concentrations are Elevated in Trauma...
PR Newswire·13d ago
News Placeholder
VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update
VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update PR...
PR Newswire·18d ago
News Placeholder
VolitionRx Reports Over 95% Early Cancer Detection in Breakthrough Liquid Biopsy Study
VolitionRx Limited (NYSE:VNRX) unveiled promising new data that could reshape the landscape of early cancer detection, reporting over 95% sensitivity in identifying stage I and II cancers using its proprietary Capture-Seq liquid biopsy technology.
24-7 Market News·18d ago
News Placeholder
VNRX Stock Soars 34% Pre-Market — What's Driving The Rally?
The company said it has developed a new liquid biopsy method, and in a blinded validation cohort, it achieved over 95% sensitivity for stage I & II cancers with 95% specificity.
Stocktwits·18d ago
News Placeholder
Volition Announces Detection of Over 95% of Early-Stage Cancers
Volition Announces Detection of Over 95% of Early-Stage Cancers Volition Announces Detection of Over 95% of Early-Stage Cancers PR Newswire HENDERSON, Nev., March 25, 2026 Blinded validation cohort...
PR Newswire·18d ago
News Placeholder
Why Is VNRX Stock Soaring Over 30% Today?
The company said it can isolate pure tumor DNA from blood, which potentially solves a key bottleneck in liquid biopsy.
Stocktwits·25d ago
News Placeholder
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating...
PR Newswire·25d ago
News Placeholder
Volition Announces First Ever Automated Nu.Q Vet Cancer Test with Fujifilm Vet Systems
Volition Announces First Ever Automated Nu.Q Vet Cancer Test with Fujifilm Vet Systems Volition Announces First Ever Automated Nu.Q Vet Cancer Test with Fujifilm Vet Systems PR Newswire HENDERSON...
PR Newswire·1mo ago
<
1
2
...
>

Latest VNRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.